Mammalian milk osteopontin for enhancing immune responsiveness

Patent metadata

Field	Value
Publication number	US-2018289798-A1
Application number	US-201815945517-A
Country	US
Kind code	A1
Filing date	Apr 4, 2018
Priority date	Jul 5, 2013
Publication date	Oct 11, 2018
Grant date	—

Abstract

The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof.

First claim

1 - 15 . (canceled)

16 . A nutritional composition for use in preventing or treating infectious disease comprising about 0.01 to about 90% w/w of mammalian milk osteopontin, wherein the osteopontin is an enriched source of purified mammalian milk osteopontin having at least 80% purity and further wherein administration of the nutritional composition prevents or treats an infectious disease selected from the group consisting of: influenza, diphtheria, tetanus, whopping cough, polio, measles, mumps, rubella, tuberculosis, hepatitis B, meningitis C, rotavirus, human papilloma virus, influenza type a, influenza type b, pneumococcal infection and shingles.

17 . The nutritional composition of claim 16 comprising about 0.1 to about 80% w/w of mammalian milk osteopontin.

18 . The nutritional composition of claim 17 , comprising about 1 to about 70% w/w of mammalian milk osteopontin.

19 . The nutritional composition of claim 16 , wherein the composition contains mammalian milk osteopontin in the range of about 0.1 mg to about 10 grams.

20 . The nutritional composition of claim 19 , wherein the composition contains mammalian milk osteopontin in the range of about 10 mg to about 800 mg.

21 . The nutritional composition of claim 16 , wherein the composition is in liquid form or powdered form.

22 . The nutritional composition of claim 16 , wherein the mammalian milk is selected from the group consisting of bovine, goat, sheep, camel, buffalo, dromedary, llama and combinations thereof.

23 . The nutritional composition of claim 16 , wherein the osteopontin is bovine and comprises an osteopontin polypeptide having an amino acid sequence of residues 17-278 of SEQ ID NO:1; and an active truncated osteopontin polypeptide of 40 kDa derived from the osteopontin polypeptide by in vivo peptide bond cleavage at a position that is C-terminal to the RGD motif.

24 . The nutritional composition of claim 16 , wherein the osteopontin is bovine and comprises an osteopontin polypeptide having an amino acid sequence of residues 17-278 of SEQ ID NO:1; and an active truncated osteopontin polypeptide wherein the amino acid sequence is residues 17-163 of SEQ ID NO:1.

25 . The nutritional composition of claim 16 , wherein the purified mammalian milk osteopontin is at least about 80% to about 90% or about 90% to about 95% pure.

26 . The nutritional composition of claim 25 , wherein the mammalian milk osteopontin is about 95% pure, about 96% pure, about 97% pure, about 98% pure, about 99% pure or about 99.5% pure.

Assignees

• Arla Foods Amba

Inventors

• Kvistgaard Anne Staudt
• Wejse Peter Langborg
• Donovan Sharon
• Siegel Marcia H Monaco
• Comstock Sarah S

Classifications

• A61K38/17 Primary

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K2039/55516

  Proteins; Peptides · CPC title

• A61K2039/55

  characterised by the host/recipient, e.g. newborn with maternal antibodies · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title